Corona Remedies Ltd
Corona Remedies Ltd (CORONA) last traded at ₹2,100, a market capitalisation of ₹12,844 crore, on a P/E of 60.5. Over the past 52 weeks the stock has ranged between ₹1,337 and ₹2,270. Corona Remedies Ltd last reported results for the quarter ended Jun 2026, with sales of ₹422 crore and net profit of ₹60 crore. The next scheduled event is an analyst meet on 26 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Corona Remedies Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Corona Remedies Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹422 cr, up 21.6% from ₹347 cr a year earlier. Net profit was ₹60 cr, up 30.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Operating profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% | 22% |
| Other income | 2 | 1 | 2 | 2 | 2 | -17 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| Profit before tax | 57 | 58 | 44 | 61 | 70 | 55 | 55 | 80 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% | 25% |
| Net profit | 43 | 45 | 32 | 46 | 52 | 41 | 45 | 60 |
| EPS (₹) | 7.03 | 7.35 | 5.16 | 7.55 | 8.55 | 6.75 | 7.41 | 9.83 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Corona Remedies Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 884 | 1,014 | 1,196 | 1,403 | 1,479 |
| Operating profit | 128 | 156 | 241 | 294 | 317 |
| OPM % | 14% | 15% | 20% | 21% | 21% |
| Net profit | 85 | 90 | 149 | 185 | 199 |
| EPS (₹) | 13.89 | 14.80 | 24.43 | 30.27 | 32.54 |
TTM is the trailing twelve months to the most recent quarter.
Corona Remedies Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 17%
- TTM
- 18%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 33%
- TTM
- 28%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 27%
- Last Year
- 30%
Corona Remedies Ltd shareholding pattern
Promoters held 69.00% at Jun 2026, broadly unchanged since Dec 2025. FIIs 3.63% and DIIs 12.90%.
| % held | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Promoters | 69.00% | 69.00% | 69.00% |
| FIIs | 1.84% | 2.25% | 3.63% |
| DIIs | 6.77% | 7.02% | 12.90% |
| Public | 22.41% | 21.75% | 14.47% |
| No. of shareholders | 31,035 | 19,609 | 20,185 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Corona Remedies Ltd events
The next scheduled event is an analyst meet on 26 Aug 2026.
- Analyst meetParticipation in Phillip Capital PCG Investor Conference
See the full results calendar for every Indian company reporting in the next 30 days.
Corona Remedies Ltd corporate filings
- Intimation of participation in Analyst / Investor ConferenceCompany Updatelow impact
Cruxal's analysis: Corona Remedies Ltd has filed an intimation regarding its participation in an…
Read the full analysis - Transcript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30, 2026Company Updatehigh impact
Cruxal's analysis: CORONA Remedies Limited delivered a robust Q1 FY27 performance, with revenue growing…
Read the full analysis - Intimation for Schedule of Analysts / Investor ConferenceCompany Updatelow impact
Cruxal's analysis: Corona Remedies Ltd has issued an intimation regarding a scheduled analyst and investor…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Corona Remedies Ltd
Cruxal reads every Corona Remedies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.